Obesity-related proliferative diseases: The interaction between adipose tissue and estrogens in post-menopausal women

Hormone Molecular Biology and Clinical Investigation

Volumn 21, Issue 1, 2015, Pages 75-87

  Vicennati, Valentina ^a   Garelli, Silvia ^a   Rinaldi, Eleonora ^a   Rosetti, Sara ^a   Zavatta, Guido ^a   Pagotto, Uberto ^a   Pasquali, Renato ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

adipose tissue; cancer; estrogens

Indexed keywords

AROMATASE; CYTOKINE; ESTROGEN; ESTROGEN RECEPTOR; TUMOR PROMOTER;

ADIPOSE TISSUE; ARTICLE; BREAST CANCER; CANCER RISK; CHRONIC INFLAMMATION; ENDOMETRIUM CANCER; ESTROGEN SYNTHESIS; FEMALE; HUMAN; HYPERINSULINEMIA; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; ANIMAL; BREAST NEOPLASMS; COMPLICATION; ENDOMETRIAL NEOPLASMS; HYPERINSULINISM; INFLAMMATION; METABOLISM;

ADIPOSE TISSUE; ANIMALS; BREAST NEOPLASMS; CYTOKINES; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HUMANS; HYPERINSULINISM; INFLAMMATION; OBESITY; POSTMENOPAUSE;

EID: 84928649986     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2015-0002     Document Type: Article

References (184)

1. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010; 15: 556-65.
2. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, Million Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ 2007; 335: 1134-9.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.
4. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-91.
5. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Bodymass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-78.
6. World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective, 2nd edition. Washington, DC: AICR, 2007.
7. International Agency for Research on Cancer. Weight control and physical activity. In: Vainio H, Bianchini F, editors. IARC Handbook of Cancer Prevention, vol. 6. Lyon: IARC Press, 2002: 1-315.
8. Kitahara CM, Platz EA, Freeman LE, Hsing AW, Linet MS, Park Y, Schairer C, Schatzkin A, Shikany JM, Berrington de Gonzalez A. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev 2011; 20: 464-72.
9. Lichtman MA. Obesity and the risk for a haematological malignancy: leukemia, lymphoma, or myeloma. Oncologist 2010; 15: 1083-101.
10. Ahn J, Schatzkin A, Lacey JV Jr, Albanes D, Ballard-Barbash R, Adams KF, Kipnis V, Mouw T, Hollenbeck AR, Leitzmann MF. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007; 167: 2091-102.
11. Hankinson SE, Colditz GA, Hunter DJ, Manson JE, Willett WC, Stampfer MJ, Longcope C, Speizer FE. Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the nurses' health study (United States). Cancer Causes Control 1995; 6: 217-24.
12. Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, Dahlgren S, Jacobson P, Karason K, Karlsson J, Larsson B, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Carlsson LM, Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009; 10: 653-62.
13. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev 2003; 4: 157-73.
14. Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, Bueno-de-Mesquita HB, Fuchs CS, Gross MD, Jacobs EJ, Lacroix AZ, Petersen GM, Stolzenberg-Solomon RZ, Zheng W, Albanes D, Amundadottir L, Bamlet WR, Barricarte A, Bingham SA, Boeing H, Boutron-Ruault MC, Buring JE, Chanock SJ, Clipp S, Gaziano JM, Giovannucci EL, Hankinson SE, Hartge P, Hoover RN, Hunter DJ, Hutchinson A, Jacobs KB, Kraft P, Lynch SM, Manjer J, Manson JE, McTiernan A, McWilliams RR, Mendelsohn JB, Michaud DS, Palli D, Rohan TE, Slimani N, Thomas G, Tjonneland A, Tobias GS, Trichopoulos D, Virtamo J, Wolpin BM, Yu K, Zeleniuch-Jacquotte A, Patel AV, Pancreatic Cancer Cohort Consortium (PanScan). Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. JAMA Intern Med 2010; 170: 791-802.
15. Friedenreich C, Cust A, Lahmann PH, Steindorf K, Boutron-Ruault MC, Clavel-Chapelon F, Mesrine S, Linseisen J, Rohrmann S, Boeing H, Pischon T, Tjonneland A, Halkjaer J, Overvad K, Mendez M, Redondo ML, Garcia CM, Larranaga N, Tormo MJ, Gurrea AB, Bingham S, Khaw KT, Allen N, Key T, Trichopoulou A, Vasilopoulou E, Trichopoulos D, Pala V, Palli D, Tumino R, Mattiello A, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Berglund G, Manjer J, Lundin E, Lukanova A, Slimani N, Jenab M, Kaaks R, Riboli E. Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. Cancer Causes Control 2007; 18: 399-413.
16. Dai Z, Xu YC, Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol 2007; 13: 4199-206.
17. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70, 000 events. Cancer Epidemiol Biomarkers Prev 2007; 16: 2533-47.
18. Steffen A, Schulze MB, Pischon T, Dietrich T, Molina E, Chirlaque MD, Barricarte A, Amiano P, Quiros JR, Tumino R, Mattiello A, Palli D, Vineis P, Agnoli C, Misirli G, Boffetta P, Kaaks R, Rohrmann S, Bueno-de-Mesquita HB, Peeters PH, May AM, Spencer EA, Allen NE, Bingham S, Tjonneland A, Halkjaer J, Overvad K, Stegger J, Manjer J, Lindkvist B, Hallmanns G, Stenling R, Lund E, Riboli E, Gonzalez CA, Boeing H. Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2009; 18: 2079-89.
19. Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol 2013; 62: 921-5.
20. Zhang C, Rexrode KM, Van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation 2008; 117: 1658-67.
21. Dirat B, Bochet L, Escourrou G, Valet P, Muller C. Unraveling the obesity and breast cancer links: a role for cancer-associated adipocytes. Endocr Dev 2010; 19: 45-52.
22. Hanahan D, Coussens LM. Accessories to the crime: functions of cell recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-22.
23. Nakajima EC, Van Houten B. Metabolic symbiosis in cancer: refocusing the Warburg lens. Mol Carcinog 2013; 52: 329-37.
24. Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Trimmer C, Tsirigos A, Migneco G, Witkiewicz AK, Balliet R, Mercier I, Wang C, Flomenberg N, Howell A, Lin Z, Caro J, Pestell RG, Sotgia F, Lisanti MP. The autophagic tumor stroma model of cancer or "battery-operated tumor growth" a simple solution to the autophagy paradox. Cell Cycle 2010; 9: 4297-306.
25. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J 2012; 279: 2610-23.
26. Friedenreich CM, Biel RK, Lau DC, Csizmadi I, Courneya K, Magliocco A, Yasui Y, Cook L. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2384-95.
27. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years observations on male British doctors. BMJ 1994; 309: 901-11.
28. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010; 61: 301-16.
29. Ziech D, Franco R, Pappa A, Panayiotidis MI. Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis. Mutant Res 2011; 711: 167-73.
30. Kim YJ, Kim EH, Hahm KB. Oxidative stress in inflammationbased gastrointestinal tract diseases: challenges and opportunities. J Gastroenterol Hepatol 2012; 27: 1004-10.
31. Guerrero J, Tobar N, Caceres M, Espinoza L, Escobar P, Dotor J, Smith PC, Martinez J. Soluble factors derived from tumor mammary cell lines induce a stromal mammary adipose reversion in human and mice adipose cells. Possible role of TGF-â1 and TNF-x. Breast Cancer Res Treat 2010; 119: 497-508.
32. Inouye KE, Shi H, Howard JK, Daly CH, Lord GM, Rollins BJ, Flier JS. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 2007; 56: 2242-50.
33. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 7265-70.
34. Khasawneh J, Schulz M, Walch A, Rozman J, Hrabe de Angelis M, Klingenspor M, Buck A, Schwaiger M, Saur D, Schmid RM, Kloppel G, Sipos B, Greten FR, Arkan MC. Inflammation and mitochondrial fatty acid â-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci USA 2009; 106: 3354-9.
35. Pou KM, Massaro JM, Hoffman U, Vasan RS, Maurovich-Horvat P, Larson MG, Keaney JF Jr, Meigs JB, Lipinska I, Kathiresan S, Murabito JM, O'Donnell CJ, Benjamin EJ, Fox CS. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress. Circulation 2007; 116: 1234-41.
36. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 2007; 28: 20-47.
37. Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol 2012; 125: 751-7.
38. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. New Engl J Med 2002; 346: 340-52.
39. Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 2010; 66: 33-8.
40. Stocco C. Tissue physiology and pathology of aromatase. Steroids 2012; 77: 27-35.
41. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M. Aromatase-a brief overview. Ann Rev Physiol 2002; 64: 93-127.
42. Chen S. Aromatase and breast cancer. Front Biosci 1998; 3: d922-33.
43. Matsumine H, Hirato K, Yanaihara T, Tamada T, Yoshida M. Aromatization by skeletal muscle. J Clin Endocrinol Metab 1986; 63: 717-20.
44. Simpson ER, Ackerman GE, Smith ME, Mendelson CR. Estrogen formation in stromal cells of adipose tissue of women: induction by glucocorticosteroids. Proc Natl Acad Sci USA 1981; 78: 5690-4.
45. MacDonald PC, Madden JD, Brenner PF, Wilson JD, Siiteri PK. Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab 1979; 49: 905-16.
46. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 1981; 53: 412-7.
47. Chow JD, Simpson ER, Boon WC. Alternative 5'-untranslated first exons of the mouse Cyp19A1 (aromatase) gene. J Steroid Biochem Mol Biol 2009; 115: 115-25.
48. Simpson ER. Aromatase: biologic relevance of tissue-specific expression. Semin Reprod Med 2004; 22: 11-23.
49. Burger HG. The endocrinology of the menopause. J Steroid Biochem Mol Biol 1999; 69: 31-5.
50. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM, Graham-Lorence S, Sun T, Fisher CR, Qin K, Mendelson CR. Aromatase expression in health and disease. Recent Progr Horm Res 1997; 52: 185-213.
51. Meseguer A, Puche C, Cabero A. Sex steroid biosynthesis in white adipose tissue. Horm Metab Res 2002; 34: 731-6.
52. Belanger C, Luu-The V, Dupont P, Tchernof A. Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab Res 2002; 34: 737-45.
53. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA. Mechanism of estrogens action. Physiol Rev 2001; 81: 1535-65.
54. Pallottini V, Bulzomi P, Galluzzo P, Martini C, Marino M. Estrogen regulation of adipose tissue functions: involvement of estrogen receptor isoform. Infect Disord Drug Targets 2008; 8: 52-60.
55. Mattson C, Olsson T. Estrogens and glucocorticoid hormones in adipose tissue metabolism. Curr Med Chem 2007; 14: 2918-24.
56. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increase adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci USA 2000; 97: 12729-34.
57. Jones ME, Thorburn AW, Britt KL, Hewitt KN, Wreford NG, Proietto J, Oz OK, Leury BJ, Robertson KM, Yao S, Simpson ER. Aromatase deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci USA 2000; 97: 12735-40.
58. Cooke PS, Naaz A. Role of estrogens in adipocyte development and function. Exp Biol Med (Maywood) 2004; 229: 1127-35.
59. Ohlsson C, Hellberg N, Parini P, Vidal O, Bohlooly-Y M, Rudling M, Lindberg MK, Warner M, Angelin B, Gustafsson JA. Obesity and disturbed lipoprotein profile in estrogen receptoralpha-deficient male mice. Biochem Biophys Res Commun 2000; 278: 640-5.
60. Naaz A, Zakroczymski M, Heine P, Taylor J, Saunders P, Lubahn D, Cooke PS. Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor alpha (ERalpha): a potential role of estrogen receptor beta (ERbeta). Horm Metab Res 2002; 34: 758-63.
61. O'Sullivan AJ. Does oestrogen allow women to store fat more efficiently? A biological advantage for fertility and gestation. Obes Rev 2009; 10: 168-77.
62. Brown LM, Clegg DJ. Central effects of estradiol in the regulation of adiposity. J Steroid Biochem Mol Biol 2010; 122: 65-73.
63. Brown LM, Gent L, Davis K, Clegg DJ. Metabolic impact of sex hormones on obesity. Brain Res 2010; 1320: 77-85.
64. Spangenburg, EE, Wohlers LM, Valencia AP. Metabolic dysfunction under reduced estrogen levels: looking to exercise for prevention. Exerc Sport Sci Rev 2012; 40: 195-203.
65. Hirschberg AL. Sex hormones, appetite and eating behaviour in women. Maturitas 2012; 71: 248-56.
66. Kim JH, Cho HT, Kim YJ. The role of estrogen in adipose tissue metabolism: insights into glucose homeostasis regulation. Endocr J 2014; 61: 1055-67.
67. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
68. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-45.
69. Rudich A, Kanety H, Bashan N. Adipose stress-sensing kinases: linking obesity to malfunction. Trends Endocrinol Metab 2007; 18: 291-9.
70. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-35.
71. Stice JP, Knowlton AA. Estrogen, NFkappaB, and the heat shock response. Mol Med 2008; 14: 517-27.
72. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl 2003; 134; 10-7.
73. Steffan RJ, Matelan E, Ashwell MA, Moore WJ, Solvibile WR, Trybulski E, Chadwick CC, Chippari S, Kenney T, Winneker RC, Eckert A, Borges-Marcucci L, Adelman SJ, Xu Z, Mosyak L, Harnish DC. Control of chronic inflammation with pathway selective estrogen receptor ligands. Curr Top Med Chem 2006; 6: 103-11.
74. Stice JP, Mbai FN, Chen L, Knowlton AA. Rapid activation of nuclear factor êb by 17â-estradiol and selective estrogen receptor modulators: pathways mediating cellular protection. Shock 2012; 38: 128-36.
75. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nature Rev Mol Cell Biol 2008; 9: 367-77.
76. Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature 2008; 454: 455-62.
77. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-7.
78. Chmelar J, Chung KJ, Chavakis T. The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance. Thromb Haemost 2013; 109: 399-406.
79. Fuentes E, Fuentes F, Vilahur G, Badimon L, Palomo I. Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators Inflamm 2013; 2013: 136584.
80. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-82.
81. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmee E, Cousin B, Sulpice T, Chamontin B, Ferrieres J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-72.
82. Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286-92.
83. Monteiro R, Soares R, Guerreiro S, Pestana D, Calhau C, Azevedo I. Red wine increases adipose tissue aromatase expression and regulates body weight and adipocyte size. Nutrition 2009; 25: 699-705.
84. Galien R, Garcia T. Etrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-êB site. Nucleic Acids Res 1997; 25: 2424-9.
85. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-êB and C/EBPê. Mol Cell Biol 1995; 15: 4971-9.
86. Guzeloglu-Kayisli O, Halis G, Taskiran S, Kayisli UA, Arici A. DNAbinding ability of NF-êB is affected differently by ERá and ERâ and its activation results in inhibition of estrogen responsiveness. Reprod Sci 2008; 15: 493-505.
87. Evans MJ, Eckert A, Lai K, Adelman SJ, Harnish DC. Reciprocal antagonism between estrogen receptor and NF-êB activity in vivo. Circ Res 2001; 89: 823-30.
88. Xing D, Oparil S, Yu H, Gong K, Feng W, Black J, Chen YF, Nozell S. Estrogen modulates NFêB signaling by enhancing IâBá levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor - Á. PLoS One 2012; 7: e36890.
89. Dodel RC, Du R, Bales KR, Gao F, Paul SM. Sodium salicylate and 17â-estradiol attenuate nuclear transcription factor NF-êB translocation in cultured rat astroglial cultures following exposure to amyloid Aê1-40 and lipopolysaccharides. J Neurochem 1999; 73: 1453-60.
90. Simoncini T, Maffei S, Basta G, Barsacchi G, Genazzani AR, Liao JK, De Caterina R. Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ Res 2000; 87: 19-25.
91. Wen Y, Yang S, Liu R, Perez E, Yi KD, Koulen P, Simpkins JW. Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia. Brain Res 2004; 1008: 147-54.
92. Liu CJ, Lo JF, Kuo CH, Chu CH, Chen LM, Tsai FJ, Tsai CH, Tzang BS, Kuo WW, Huang CY. Akt mediates 17â-estradiol and/or estrogen receptor-á inhibition of LPS-induced tumor necrosis factor-á expression and myocardial cell apoptosis by suppressing the JNK1/2-NFêB pathway. J Cell Mol Med 2009; 13: 3655-67.
93. Vona-Davis L, Rose DP. The obesity-inflammation-eicosanoid axis in breast cancer. J Mammary Gland Biol Neoplasia 2013; 18: 291-307.
94. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer 2009; 124: 698-712.
95. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S. Hormonal factors and the risk of breast cancer according to estrogen-and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev 2003; 12: 1053-60.
96. Niraula S, Ocana A, Ennis M, Goodwin PJ. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 2012; 134: 769-81.
97. Bulun SE, Chen D, Moy I, Brooks DC, Zhao H. Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 2012; 23: 83-9.
98. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007; 14: 189-206.
99. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, Zhou XK, Blaho VA, Hla T, Yang P, Kopelovich L, Hudis CA, Dannenberg AJ. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 2011; 4: 329-46.
100. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, Du B, Brogi E, Crawford CB, Kopelovich L, Subbaramaiah K, Dannenberg AJ. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 2011; 4: 1021-9.
101. Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediat Inflamm 2010; 2010: 513948.
102. Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, Wabitsch M, O'Brien PE, Harrison LC. Proinflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 2010; 59: 1648-56.
103. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455-60.
104. Singh-Ranger G, Kirkpatrick KL, Clark GM, Mokbel K. Cyclo-oxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer. Curr Med Res Opin 2003; 19: 131-34.
105. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004; 90: 423-9.
106. Tan KB, Yong WP, Putti TC. Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology 2004; 44: 24-8.
107. Nakopoulou L, Mylona E, Papadaki I, Kapranou A, Giannopoulou I, Markaki S, Keramopoulos A. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology 2005; 72: 241-9.
108. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology 2005; 46: 561-8.
109. Takeshita E, Osanai T, Higuchi T, Soumaoro LT, Sugihara K. Elevated cyclooxygenase-2 expression is associated with histological grade in invasive ductal breast carcinoma. J Med Dent Sci 2005; 52: 189-93.
110. Karmali RA, Marsh J. Antitumor activity in a rat mammary adenocarcinoma: the effect of cyclooxygenase inhibitors and immunization against prostaglandin E2. Prostaglandins Leukot Med 1985; 20: 283-6.
111. Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999; 83: 217-44.
112. Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol 2014; 5: 677-92.
113. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46: 2347-55.
114. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, Kopelovich L, Hudis CA, Dannenberg AJ. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012; 2: 356-65.
115. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol 2013; 33(Suppl 1): S79-84.
116. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996; 137: 5739-42.
117. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999; 140: 27-35.
118. Richards JA, Brueggemeier RW. Interactions of cyclooxygenase and aromatase pathways in normal and malignant breast cells. In: Harris RE, editor. COX-2 Blockade in cancer prevention and therapy. Totowa: Humana Press, 2002: 205-24.
119. Diaz-Cruz ES, Brueggemeier RW. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem 2006; 6: 221-32.
120. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23: 254-66.
121. Bhattacharjee RN, Timoshenko AV, Cai J, Lala PK. Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer. Cancer Sci 2010; 101: 2026-32.
122. Whelan J, McEntee MF. Nonsteroidal anti-inflammatory drugs, prostaglandins, and APC-driven intestinal tumorigenesis. In: Harris RE, editor. COX-2 Blockade in cancer prevention and therapy. Totowa: Humana Press, 2002: 117-45.
123. Australian Institute of Health and Welfare, Australian Association of Cancer Registries. Cancer in Australia 1999. Canberra: AIHW and Australian Association of Cancer Registries, 2002.
124. Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005; 14: 1132-42.
125. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
126. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS 2009; 117: 693-707.
127. Sivridis E, Fox H, Buckley C. Endometrial carcinoma: two or three entities? Int J Gynecol Cancer 1998; 8: 183-8.
128. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a gynecologic oncology group study. Cancer 2006; 106: 812-9.
129. Uharcek P. Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res 2008; 34: 776-83.
130. Austin H, Austin Jr JM, Partridge EE, Hatch KD, Shingleton HM. Endometrial cancer, obesity, and body fat distribution. Cancer Res 1991; 51: 568-72.
131. Olson SH, Trevisan M, Marshall JR, Graham S, Zielezny M, Vena JE, Hellmann R, Freudenheim JL. Body mass index, weight gain, and risk of endometrial cancer. Nutr Cancer 1995; 23: 141-9.
132. Baanders-van Halewyn EA, Blankenstein MA, Thijssen JH, de Ridder CM, de Waard F. A comparative study of risk factors for hyperplasia and cancer of the endometrium. Eur J Cancer Prev 1996; 5: 105-12.
133. Hirose K, Tajima K, Hamajima N, Takezaki T, Inoue M, Kuroishi T, Kuzuya K, Nakamura S, Tokudome S. Subsite (cervix/endometrium)-specific risk and protective factors in uterus cancer. Jpn J Cancer Res 1996; 87: 1001-9.
134. Kalandidi A, Tzonou A, Lipworth L, Gamatsi I, Filippa D, Trichopoulos D. A case-control study of endometrial cancer in relation to reproductive, somatometric, and life-style variables. Oncology 1996; 53: 354-9.
135. Kelsey JL, LiVolsi VA, Holford TR, Fischer DB, Mostow ED, Schwartz PE, O'Connor T, White C. A case-control study of cancer of the endometrium. Am J Epidemiol 1982; 116: 333-42.
136. La Vecchia C, Parazzini F, Negri E, Fasoli M, Gentile A, Franceschi S. Anthropometric indicators of endometrial cancer risk. Eur J Cancer 1991; 27: 487-90.
137. Ricci E, Moroni S, Parazzini F, Surace M, Benzi G, Salerio B, Polverino G, La Vecchia C. Risk factors for endometrial hyperplasia: results from a case-control study. Int J Gynecol Cancer 2002; 12: 257-60.
138. Goodman MT, Hankin JH, Wilkens LR, Lyu LC, McDuffie K, Liu LQ, Kolonel LN. Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res 1997; 57: 5077-85.
139. Levi F, La Vecchia C, Negri E, Parazzini F, Franceschi S. Body mass at different ages and subsequent endometrial cancer risk. Int J Cancer 1992; 50: 567-71.
140. Chang SC, Lacey JV Jr, Brinton LA, Hartge P, Adams K, Mouw T, Carroll L, Hollenbeck A, Schatzkin A, Leitzmann MF. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 2007; 16: 723-30.
141. Siiteri PK. Steroid hormones and endometrial cancer. Cancer Res 1978; 38: 4360-6.
142. Judd HL. Hormonal dynamics associated with the menopause. Clin Obstet Gynecol 1976; 19: 775-88.
143. Cleland WH, Mendelson CR, Simpson ER. Effects of aging and obesity on aromatase activity of human adipose cells. J Clin Endocrinol Metab 1985; 60: 174-7.
144. Sasano H, Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev 1998; 19: 593-607.
145. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr 1987; 45(Suppl 1): 277-82.
146. Nagamani M, Hannigan EV, Dillard EA Jr, Van Dinh T. Ovarian steroid secretion in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab 1986; 62: 508-12.
147. Mollerstrom G, Carlstrom K, Lagrelius A, Einhorn N. Is there an altered steroid profile in patients with endometrial carcinoma? Cancer 1993; 72: 173-81.
148. Knab DR. Estrogen and endometrial carcinoma. Obstet Gynecol Surv 1977; 32: 267-81.
149. Tseng L, Mazella J, Funt MI, Mann WJ, Stone ML. Preliminary studies of aromatase in human neoplastic endometrium. Obstet Gynecol 1984; 63: 150-4.
150. Wynder EL, Escher GC, Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer 1966; 19: 489-520.
151. Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974; 38: 476-9.
152. Southcott BM. Carcinoma of the endometrium. Drugs 2001; 61: 1395-405.
153. Lachance JA, Everett EN, Greer B, Mandel L, Swisher E, Tamimi H, Goff B. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2006; 101: 470-5.
154. Burbos N, Musonda P, Giarenis I, Shiner AM, Giamougiannis P, Morris EP, Nieto JJ. Predicting the risk of endometrial cancer in postmenopausal women presenting with vaginal bleeding: the Norwich DEFAB risk assessment tool. Br J Cancer 2010; 102: 1201-6.
155. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, Peeters PH, Onland-Moret NC, Lahmann PH, Berrino F, Panico S, Larranaga N, Pera G, Tormo MJ, Sanchez MJ, Ramon Quiros J, Ardanaz E, Tjonneland A, Olsen A, Chang-Claude J, Linseisen J, Schulz M, Boeing H, Lundin E, Palli D, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Bingham S, Khaw KT, Bueno-de-Mesquita HB, Trichopoulou A, Trichopoulos D, Naska A, Tumino R, Riboli E, Kaaks R. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008; 15: 485-97.
156. Kirschner MA, Schneider G, Ertel NH, Worton E. Obesity, androgens, estrogens, and cancer risk. Cancer Res 1982; 42(Suppl 8): 3281-5.
157. Pettersson B, Bergstrom R, Johansson ED. Serum estrogens and androgens in women with endometrial carcinoma. Gynecol Oncol 1986; 25: 223-33.
158. Azziz R. Reproductive endocrinologic alterations in female asymptomatic obesity. Fertil Steril 1989; 52: 703-25.
159. Nyholm HC, Nielsen AL, Lyndrup J, Dreisler A, Hagen C, Haug E. Plasma oestrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynaecol 1993; 100: 1115-9.
160. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY, Levitz M, Mittal KR, Raju U, Banerjee S, Toniolo P. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001; 84: 975-81.
161. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, Krogh V, Lenner P, Shore RE, Biessy C, Muti P, Riboli E, Koenig KL, Levitz M, Stattin P, Berrino F, Hallmans G, Kaaks R, Toniolo P, Zeleniuch-Jacquotte A. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004; 108: 425-32.
162. Chang RJ, Judd HL. The ovary after menopause. Clin Obstet Gynecol 1981; 24: 181-91.
163. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Persky V, Lurain JR. Case control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996; 88: 1127-35.
164. Aiman J. Age, estrogen, and the endometrium. Clin Obstet Gynecol 1981; 24: 193-202.
165. Jongen VH, Hollema H, Van Der Zee AG, Heineman MJ. Aromatase in the context of breast and endometrial cancer. A review. Minerva Endocrinol 2006; 31: 47-60.
166. Murphy LJ, Ghahary A. Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev 1990; 11: 443-53.
167. Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335: 640-9.
168. Weiss NS, Hill DA. Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Maturitas 1996; 23: 235-9.
169. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000; 7: 227-42.
170. Lundberg V, Tolonen H, Stegmayr B, Kuulasmaa K, Asplund K, WHO MONICA Project. Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas 2004; 48: 39-49.
171. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293: 1167-70.
172. Mack TM, Pike MC, Henderson BE, Pfeffer RI, Gerkins VR, Arthur M, Brown SE. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976; 294: 1262-7.
173. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978; 130: 448-55.
174. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R. Endometrial cancer and estrogen use. Report of a large casecontrol study. N Engl J Med 1979; 300: 9-13.
175. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304-13.
176. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458-61.
177. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999; 10: 277-84.
178. Beral V, Reeves G, Banks E. Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. BJOG 2005; 112: 692-5.
179. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274-7.
180. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001; 91: 421-30.
181. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002; 11: 1531-3.
182. Polednak AP. Trends in incidence rates for obesity-associated cancers in the US. Cancer Detect Prev 2003; 27: 415-21.
183. Bray F, Loos AH, Oostindier M, Weiderpass E. Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre-and postmenopausal women in Europe. Int J Cancer 2005; 117: 123-31.
184. Lepine J, Audet-Walsh E, Gregoire J, Tetu B, Plante M, Menard V, Ayotte P, Brisson J, Caron P, Villeneuve L, Belanger A, Guillemette C. Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab 2010; 95: 2689-98.